PTC Italy recently won two distinct industry awards in innovation, leadership and patient-centricity: the Le Fonti Award for Excellence in Biopharmaceutical Innovation & Leadership of the Year and The Excellence of Scientific Information and the Centrality of the Patient Award.
At the thirteenth edition of the Le Fonti Awards, PTC was honored to accept the award for Excellence in Biopharmaceutical Innovation & Leadership of the Year. The prestigious award recognized PTC for “the constant commitment to small molecules and innovative gene therapies for rare genetic diseases. For the teamwork that pushes research to high levels, for the use of the most recent technologies and for the patient-oriented therapeutic approach.” This is the fifth consecutive year that PTC Italy has won the award!
The Le Fonti Awards is a key annual awards ceremony that rewards companies, legal and professional firms that have distinguished themselves due to their specialization, high levels of excellence, leadership, innovation and competitiveness. The award ceremony took place on June 29, 2023, in the splendid setting of Palazzo Mezzanotte, headquarters of Borsa Italiana. For more information visit https://www.lefontiawards.it/
PTC was also named a winner in the rare disease and orphan drugs category at the seventh edition of the award, “The Excellence of Scientific Information and the Centrality of the Patient”.
The special prize recognized PTC’s efforts in addressing knowledge and literacy about AADC deficiency, an ultra-rare disease which if often overlooked, misdiagnosed or even un-diagnosed and not well understood among many physicians. PTC’s information campaign aimed to support prompt recognition of the signs and symptoms, the process of testing and screening to accelerate diagnosis of AADC deficiency among patients.
To date, the campaign has yielded positive metrics indicating interest in educational content among physicians as well as requests for further resources and materials. Experience and learnings from the campaign show that diagnosing an ultra-rare disease is challenging and there are no simple solutions to complex problems. All tools and resources must be used in a coordinated and continuous manner.
Riccardo Ena Head of Spain, Italy & Portugal at PTC TherapeuticsPTC is committed to serving patients and supporting all stakeholders in the provision of care. We are proud to be able to make a positive impact with our efforts and be recognized with this award.